ROUND ROCK, Texas, Sept. 28, 2019 /PRNewswire/ -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) is pleased to join several organizations as a sponsor of the third annual National Penicillin Allergy Day, an awareness day to help educate the community on penicillin allergies and the importance of testing to ensure proper diagnosis. The day is celebrated on

HOUSTON and VANCOUVER, Sept. 28, 2019 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the 2019 American Urological Association ("

SALT LAKE CITY, Sept. 28, 2019 /PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today presented new data from the ongoing Phase 1 study evaluating the maximum tolerated dose (MTD) of the oral investigational agent TP-0903, an AXL receptor tyrosine kinase (RTK) inhib

FRAMINGHAM, Mass., Sept. 28, 2019 /PRNewswire/ -- BERG, a clinical stage biopharmaceutical company that utilizes artificial intelligence (AI) and multi-omics to identify novel biology and disease modifying targets, today announced results from a predictive analysis of adverse events by the BERG platform, for a multi-center Phase 1 study evaluating BPM31510 (novel ubideca

WHIPPANY, N.J., Sept. 28, 2019 /PRNewswire/ -- Updated clinical data for Vitrakvi® (larotrectinib) in adult and pediatric patients with TRK fusion cancer demonstrated an overall response rate (ORR) of 79 percent (n=121; 95% CI, 72–85), including 16 percent complete responses (CR) and 63 percent partial responses (PR) per investigator assessment.

LONDON, Sept. 28, 2019 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced GSK3359609, an inducible T cell co-stimulatory (ICOS) agonist antibody designed to selectively enhance T cell function, showed promising anti-tumour activity in combination with pembrolizumab in PD-1/L1 naive patients with head and neck squamous cell carcino

BOTHELL, Wash. and TOKYO, Sept. 28, 2019 /PRNewswire/ -- 

THOUSAND OAKS, Calif., Sept. 27, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutant solid tumors. The data include the first evidence of anti-tumor activity reported in patients with colorectal cancer (CRC) and appendiceal cancer, as well as

SHANGHAI and NEW YORK, Sept. 27, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that a drug application* for its off-the-shelf autologous adip

NEW YORK, Sept. 27, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating the proposed merger of Avedro, Inc. ("Avedro" or the "Company") (NASDAQ: AVDR) with Glaukos Corporation ("Glaukos").